Sapient publishes breakthrough rLC-MS metabolomics study in over 26,000 samples

The study, which analyzed 26,042 samples from 6,935 individuals with diverse demographic backgrounds and disease profiles, exemplifies the critical insights that can be extracted from large-scale, non-targeted metabolomics analyses.

The paper describes key findings including discovery of clinically relevant "metabotypes" that correlate with common diseases and development of a metabolic aging clock model trained on the metabolomics data, which accurately predicted accelerated aging in various chronic diseases and showed dynamic reversal of aging following definitive therapy.

From IHC to Mass Spectrometry: Expanding Possibilities in Clinical Protein Analysis

White Paper: Explore why modern clinical research requires advanced protein assays that bridge the analysis gap from observation to interpretation of proteins in tissue to drive deeper molecular insight.

Enhancing Omics Data Integrity: A Principled Approach to PCA-Based Quality Assessment

Article: Detailing best practices for PCA quality assessment workflows critical to enhance the reproducibility of findings in multi-omics datasets and enable credible scientific discovery.

Beyond DNA and RNA: Exposing What Sequencing Misses in Target ID and Biomarker Discovery

Webinar: Why proteomics, which enables mapping of non-canonical or "dark proteins", is critical to move beyond traditional known targets & biomarkers.

Turning back the metabolic aging clock

Case Study: Can dynamic metabolomics data be used to predict individual biological aging rates better than biomedical data or epigenetic markers alone? We trained a machine learning model on rLC-MS generated data to find out.

 Discover approaches to rapidly unify and leverage multi-omics & real-world data for drug development

Interested in how vast amounts of disparate life science data can be transformed into actionable insights for accelerated drug development?

In this webinar, we share how we partnered with Rancho Biosciences to bring Sapient’s DynamiQ™ Insights Engine – our large-scale multi-omics and RWD database – to life as a cutting-edge data lakehouse, and the analyses it enables to decipher dynamic disease mechanisms, stratify patient populations, and inform better treatment strategies.

Smart Biotech Scientist Podcast: Dr. Mo Jain on why drug development is due for disruption

Sapient's Founder and CSO talks about the power of multi-omics to transform drug development efficiencies by illuminating the missing 80-90% of disease risk not explained by genetics. Click to listen.

Exciting turnout at Biomarkers & Precision Medicine 2025 session

Thank you to everyone who attended Sapient's talk the recent Oxford Global conference. We had a crowd of over 90 people at the session discussing the emerging role of next generation multi-omics in biomarker-driven drug development.

If you couldn't make the event, we'd be happy to share key takeaways from our discussions. Reach out here.

Discovery and Development US 2025

October 2-3

San Diego, CA

Reach out to schedule a meeting or a time to tour our lab in Sorrento Valley! 

ASHG 2025

October 14-18

Boston, MA

Set up a time to connect with our attending team during this flagship conference on human genetics.

Ready to discover more?

10421 Wateridge Circle, Suite 100
San Diego, CA 92121

858.290.7010

©2025 Sapient Bioanalytics, LLC. All rights reserved.